Zai Lab’s zocilurtatug pelitecan secures EMA orphan drug status
Zai Lab has received ODD from the EMA for zocilurtatug pelitecan (zoci), its investigational DLL3-targeting ADC for treating pulmonary NECs.
Read the full article on the original site.
Read Full Article